Technical Articles
UA016082
Clinical Setbacks of IGF1R Antibodies: From Figitumumab Monotherapy to a Combination-Treatment Paradigm Shift
2026-10-08After figitumumab monotherapy failed, the IGF1R antibody field shifted toward combination treatment and biomarker stratification. This article traces the paradigm shift in IGF1R translational research and its in vitro tool support.
View details
- Cancer
- IGF1R antibodies
- figitumumab
- ganitumab
- combination therapy
- biomarkers
- tumor targeting
- UA016082
- alpha2beta2
IGF1R/CD221: Structure, alpha2beta2 Assembly and the Tumor Research Landscape of a Receptor Tyrosine Kinase
2026-10-08IGF1R/CD221 is a receptor tyrosine kinase of the insulin receptor family, assembled as an alpha2beta2 heterotetramer. This review covers its molecular architecture, IGF-1/IGF-2 ligand recognition, PI3K-AKT and RAS-RAF-MEK-ERK signaling, and key point
View details
- Cancer
- IGF1R
- CD221
- alpha2beta2
- RTK
- IGF-1
- IGF-2
- PI3K/AKT
- RAS/RAF/MEK/ERK
- UA016082
CD221/IGF1R Fc Chimeric Protein Binding Assays: Ligands, Conditions and Interpretation
2026-10-08CD221/IGF1R Fc chimeric protein is a research tool for IGF-2 binding studies. This article covers Fc fusion design, HEK293-derived antigen QC, ELISA platform parameters and a three-class control troubleshooting path.
View details
- Cancer
- CD221
- IGF1R
- Fc chimeric protein
- IGF-2 binding
- ELISA
- EC50
- UA016082
- alpha2beta2
- RTK
- 1
Link：
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy 
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
Business license (three certificates in one) Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.
